This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Complementary and Alternative Medicine  • Malaria  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2005;293:785-787.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Curing a disease in developing countries takes more than designing an effective medicine because pharmaceutical companies have little incentive to produce a drug that will not turn a large profit. But a recent collaboration of three California organizations—a nonprofit institute, a biotech company, and a university—could help change that paradigm.

A $42.6 million grant from the Bill and Melinda Gates Foundation will help the Institute for OneWorld Health, in San Francisco; Amyris Biotechnologies Inc, in Albany, Calif; and the University of California at Berkeley apply a breakthrough technology to the production of the antimalarial drug artemisinin for developing countries. Scientists at the University of California at Berkeley will conduct the necessary research and development, OneWorld Health will work to clear regulatory hurdles, and Amyris will scale up production of the drug. And all three organizations will come out ahead.

Artemisinin, a potent antimalarial drug derived from the . . . [Full Text of this Article]

PROBLEMS WITH ARTEMISININ